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The alternative lengthening of telomeres (ALT) is a recombination-based mechanism of telomere maintenance activated in 5–20%
of human cancers. In Saccharomycescerevisiae,survivorsthatariseafterinactivation oftelomerasecan beclassiﬁedas typeIortype
II ALT. In type I, telomeres have a tandem array structure, with each subunit consisting of a subtelomeric Y  element and short
telomere sequence. Telomeres in type II have only long telomere repeats and require Sgs1, the S. cerevisiae RecQ family helicase.
We previously described the ﬁrst human ALT cell line, AG11395, that has a telomere structure similar to type I ALT yeast cells.
This cell line lacks the activity of the Werner syndrome protein, a human RecQ helicase. The telomeres in this cell line consist of
tandem repeats containing SV40 DNA, including the origin of replication, and telomere sequence. We investigated the role of the
SV40 origin of replication and the eﬀects of Werner protein and telomerase on telomere structure and maintenance in AG11395
cells. We report that the expression of Werner protein facilitates the transition in human cells of ALT type I like telomeres to type
II like telomeres in some aspects. These ﬁndings have implications for the diagnosis and treatment of cancer.
1.Introduction
As progressive loss of telomere DNA is associated with senes-
cence [1], maintenance of telomere function is essential for
indeﬁnite cell proliferation. Most cancer cells rely on expres-
sion of telomerase for suppression of telomere shortening
[2].However5%–20%percentofcancersmaintaintelomeres
by the alternative lengthening of telomere (ALT), a recom-
bination-based mechanism [3].
Telomere maintenance mechanisms are a potential prog-
nostic indicator [3] and promising target in cancer diagnosis
and therapy [4–6]. Increasing evidence supports that Werner
protein (WRN), a RecQ helicase and exonuclease, plays a
direct role in telomere maintenance [7] and promotion of
tumor cell growth [8]. WRN epigenetic silencing in human
cancers leads to hypersensitivity to treatment with a number
of chemotherapeutic drugs [9]. Germline mutations in the
WRN gene cause an autosomal recessive disorder, Werner
syndrome(WS).WSischaracterizedbysymptomssuggestive
of premature aging and by the development of mesenchymal
neoplasms [10]. Strikingly, the ALT mechanism is more pre-
valent in tumors arising from tissues of mesenchymal origin,
such as osteosarcomas, than in those of epithelial origin [11].
It has been suggested that the telomere-telomere recombina-
tion in WRN-deﬁcient, telomere dysfunctional cells pro-
motes escape from senescence and engagement of the ALT
pathway [12]. Werner protein also colocalizes with telomeres
in human ALT cells [13].
S. cerevisiae cells that lack functional telomerase undergo
telomere attrition and lose viability [14]. Rare cells escape
senescence and two types of survivors arise. Type I ALT
survivors have telomeres that have a tandem array structure.
The repeat unit in the array consists of a subtelomeric Y 
element containing an ARS (yeast origin of replication)2 Journal of Oncology
associated with short telomeric TG1−3 repeats. This repeat
unit is ampliﬁed as a tandem array structure at chromosome
termini. Type II survivors have little or no ampliﬁcation of
Y  elements, but instead have long, heterogeneous, TG1−3 re-
peats extending up to several kilobase pairs (kbp) [15, 16].
The generation of type I cells depends on expression of pro-
teins involved in recombination, including RAD52 and
RAD51.TypeIIcellsdependonexpressionofSgs1,theS.cer-
evisiae RecQ family helicase, in addition to recombination
proteinsRAD52andRAD50[13,17].WRNcancomplement
Sgs1 deﬁciency in type II ALT cells of S. cerevisiae [17]. Sgs1
deletion also facilitates the generation of survivors that grow
independent of Rad52. Although tlc1rad52 yeast does not
form survivors of telomere dysfunction, tlc1rad52sgs1 triple
mutants readily generated survivors [18].
Nearly all of the human ALT cell lines analyzed to date
havecharacteristicssimilar tothatofS. cerevisiae typeIIALT.
M o s th u m a nA L Tc e l l sh a v el o n ga n dh e t e r o g e n e o u st e l o -
meres, ranging from 2 to 20kb within an individual cell
and have ALT-associated promyelocytic leukemia bodies
(APBs) [19]. APBs contain the constitutive components of
promyelocytic leukemia bodies, telomere DNA, and the pro-
teinsinvolvedinDNAreplicationandrecombinationinclud-
ing RAD51, RAD52, RAD50, and WRN [3].
One immortalized human cell line has a “tandem array”
telomere structure similar to that of type I ALT in yeast [20,
21]. AG11395 is an SV40 T-antigen transformed, immortal-
ized ﬁbroblast cell line derived from an individual diagnosed
with Werner syndrome [22]. It does not contain APBs and
lacks the Werner syndrome protein. The chromosome termi-
ni of AG11395 consist of a repeat unit containing 2.5kb of
SV40 DNA and a variable amount of TTAGGG telomere seq-
uencerepeats.TheSV40DNAintegratedintothetelomerein
this cell line contains the regulatory regions, which include
the origin of replication and the early and late promoter seq-
uences [21]. This cell line oﬀers a unique system to inves-
tigate the role of the WRN protein and tandem array telo-
meres in human ALT telomere maintenance. Here we deter-
mine whether telomere maintenance in AG11395 involves a
functioning SV40 origin of replication and we describe the
eﬀect on type I like structures of expression of WRN protein.
2.MaterialsandMethods
2.1. Cell Lines and Culture. AG11395, WI38 75.1, and
GM847 were obtained from the Coriell Cell Repository (Ca-
mden, NJ). HeLa and COS cells were obtained from the
American Type Culture Collection (Manassas, VA). Cells
w e r eg r o w ni n5 %C O 2 under conditions recommended by
the supplier.
2.2. Quantitative Polymerase Chain Reaction (qPCR). To
determine whether in AG11395 the SV40 origin of replica-
tion integrated at telomeres is functioning, we cotransfected
pRLSV40 (Promega. Madison, WI) that has SV40 origin
of replication and pRLCMV (Promega. Madison, WI) that
does not contain an SV40 origin of replication in a 1:1
ratio in AG11395. The ratio of pRLSV40 to pRLCMV was
assessed by qPCR, with primers speciﬁc to each plasmid us-
ing Express SYBR Green qPCR reagents (Invitrogen) in a
Mx3000P thermal cycler (Stratagene, La Jolla, CA).
The primers used included
pRLSV40-forward primer: 5 -GGCTTTTTTGGAG-
GCCTAGG-3 
pRLSV40-reverse primer: 5 -CGAGACTGTTGTGT-
CAGAAGAATCA-3 
pRLCMV-forward primer: 5 -CGTGTACGGTGGG-
AGGTC-3 
pRLCMV-reverse primer: 5 -CAATAAAGCTTCTA-
GTGATCTGACG-3 
SV40 regulatory sequences before and after WRN
expression were quantiﬁed by qPCR with the follow-
ing primers:
5 -CCT CAG TAA GCA CAG CAA GCA T-3 
5 -AAT GGC CTG AGT GTG CAA AGA-3 
For internal control, the β-globin gene was ampliﬁed with
5 -TGA AGG CTC ATG GCA AGA AA-3 
5 -GGT GAG CCA GGC CAT CAC-3 
Ampliﬁcation conditions for all qPCR were 10 minutes at
95◦C, followed by 30 cycles of 30 seconds at 95◦C followed
by 60 seconds at 60◦C.
2.3. Retroviral Infection. To produce infectious retrovirus,
the phoenix packaging cell line (kindly provided by Dr.
Garry P. Nolan, Stanford University) was transfected with
pLXIN (Clontech, Mountain View, CA) and pLXIN/WRN
using Fugene-6 (Roche Applied Sciences, Indianapolis, IN)
per the manufacturer’s instructions. Forty-eight hours after
transfection,supernatantwasﬁlteredthrougha0.45μmﬁlter
to obtain a cell-free stock of virus. The viral supernatant was
addedtoAG11395cellsandincubated24hours.Theinfected
cells were selected by addition of 200μg/mL G418 (Sigma,
St. Louis, MO). To produce cell lines expressing telomerase
reverse transcriptase, pBABE/hTERT and pBABE/hTERT
HA (Robert Weinberg, M.I.T.) were used as described above
with the exception that infected cells were selected by addi-
tion of 0.1μg/mL puromycin (Mediatech, Manassas, VA).
The puromycin-selected telomerase expressing cells were
tested as a mixed population. Given greater heterogeneity
of expression in the WRN expressing clones, 3 individual
subclones were isolated and selected for further study.
2.4. Western Blots. Ten micrograms of protein extract were
resolved on an 8% SDS-PAGE gel and transferred to HyBond
ECL membrane (New England Nuclear, Boston, MA). Aﬃn-
ity puriﬁed polyclonal rabbit anti-Werner and monoclonal
mouse anti-actin antibodies (Abcam, Cambridge, MA) were
usedatadilutionof1:1000.Westernblottingwasperformed
as described [23].Journal of Oncology 3
2.5. Indirect Immunoﬂuorescence. Fixation and indirect im-
munoﬂuorescence were done as described [24]. Antibodies
anddilutionsusedweremousemonoclonalanti-PML(Santa
Cruz Biotech, Santa Cruz, CA) at a dilution of 1:100, anti-
TRF1 (hybridoma supernatant 4E4, GeneTex, San Antonio,
TX), at a dilution of 1:5, and aﬃnity-puriﬁed polyclonal
rabbit anti-Werner antibody was used at a dilution of 1:100.
Cy3-conjugated anti-mouse (Molecular Probes, Carlsbad,
CA) and FITC-conjugated anti-rabbit (Jackson labs, Bar
Harbor, ME) at a dilution of 1:300 were used to detect
anti-TRF1 anti-PML and anti-Werner. Nuclei were counter-
stained with 4,6-diamidino-2-phenylindole dihydrochloride
(DAPI) at a concentration of 100ng/mL. Immunoﬂuores-
cenceimageswere obtained using a Nikon Eclipse TE200 mi-
croscopy system.
2.6. Telomerase Enzymatic Assays. Telomerase enzymatic ac-
tivity was detected using the TRAPeze telomerase detection
kit (Chemicon, Temecula, CA).
2.7.QuantiﬁcationofTelomereLengthbyQuantitativeFluore-
scent In Situ Hybridization (Q-FISH). Telomere lengths were
quantiﬁed in arbitrary ﬂuorescence units (AFUs) using a pe-
ptide nucleic acid (PNA) probe directly labeled with a Cy3
(Applied Biosystems, Foster City, CA) as previously descri-
bed [25]. Cells were harvested by centrifugation at 200 ×g.
The pellet was resuspended in hypotonic KCl (0.067M) for
5minat37 ◦C and then ﬁxed and washed in methanol/acetic
acid (3:1). Q-FISH was performed as described by Poon
and Lansdorp [25]. Brieﬂy, ﬁxed metaphase nuclei were
dropped onto slides, hybridized withPNA probe, and images
of telomeres and chromosomes were captured using digital
ﬂuorescence microscopy. The images were analyzed with the
TFL-Telo program to detect the telomere-speciﬁc ﬂuores-
cence signal. To compensate the inter-specimen hybridiza-
tionﬂuctuation,plasmidscontaining1.6kb,and800bptelo-
mere sequence were used as control. To check any variation
in lamp or alignment of the optics, we measured the integra-
ted ﬂuorescence intensity (IFI) of 0.1μmb e a d sf o rn o r m a l -
ization between diﬀerent experiments [25]. All experiments
within a set in which quantitative length comparisons were
made were dropped, hybridized, and analyzed in parallel at
onetimetominimizeeﬀectsofprobeintegrity,hybridization
eﬃciency or drift in the performance of the optical system.
2.8. Chromosome Orientation-FISH (CO-FISH). Telomere
sister chromatid exchange (T-SCE) was performed using
chromosome-orientation-speciﬁc ﬂuorescence in situ hybri-
dization (CO-FISH). CO-FISH procedure was performed as
described in [26]. Brieﬂy, during S-phase, Bromodeoxyuri-
dine (BrdU) and Bromodeoxycytidine (BrdC) nucleotides
areincorporatedinto thenewlysynthesized DNAduring one
cell division. The BrdU-substituted DNA strands are degrad-
ed by Hoechst dye, UV, and exonuclease treatments. The
parental G-rich and C-rich strands are visualized on the sin-
gle-strandedsisterchromatidsbyspeciﬁcprobeslabeledwith
Cy3 (against the G-rich strand) or FITC (against the C-rich
strand).
2.9. Combined IF/PNA FISH. Colocalization of PML protein
with telomeres in WRN expressing AG11395 was conﬁrmed
by IF/FISH, with IF performed as described above. After
incubation with secondary antibody, the immune complexes
were cross-linked with 4% paraformaldehyde, dehydrated
andprocessedforPNAFISH,asdescribedforQ-FISHabove.
3. Results
3.1. AG11395 Does Not Support the Replication of the SV40
Origin of Replication. The telomeres of AG11395 contain an
SV40 sequence, which includes a wild-type sequence origin
of replication [21]. One possible function of the nontelo-
mere repeat sequence integrated into the telomeres of cell
lineAG11395couldbetoprovideafunctionaloriginofrepli-
cation integrated at telomeres. The Y  element found integ-
rated into the telomeres of type I survivors of telomere-
induced senescence in S. cerevisiae contains a yeast autono-
mously replicating sequence (ARS) [27]. The ARSs in Y 
elements are nonfunctional in the proximity of telomere seq-
uences[28,29].ToassesswhetheranySV40originofreplica-
tion is functional in cell line AG11395, we determined whe-
ther a plasmid containing a wild-type origin of replication
would be replicated when transfected into this cell line
(Figure 1). We co-transfected pRLSV40, which contains a
functional SV40 origin of replication, and pRLCMV, which
does not contain an SV40 origin of replication. Replication
of the SV40 origin containing plasmid is measured as an in-
crease in the ratio of pRLSV40 to pRLCMV DNA, as measur-
ed by qPCR. In addition, we tested whether inhibitors of
replication of SV40 were present in the cell lines by additio-
nally cotransfecting pBRSV40, which expresses wild-type
SV40 T-antigen. As carrier DNA in those experiments was
not including pBRSV40, plasmid pEGFP was used, allowing
for visual monitoring of transfection eﬃciency (Figure 1(a)).
SV40 origin containing plasmid replication was assessed
in 3 cell lines: AG11395, WI38 75.1 (an SV40-transformed,
T-antigen expressing, ALT ﬁbroblast cell line), and COS
(which eﬃciently supports replication directed by the SV40
origin).Demonstratingthatthismethodology formeasuring
plasmid replication is functioning, we observed a substantial
increase in the pRLSV40/pRLCMV ratio in COS cells, both
with and without T-antigen provided in trans by transfec-
tion of plasmid pBRSV40 (Figure 1(a)). Neither AG11395
nor WI38 75.1 supported replication of the SV40 origin con-
taining plasmid without expression of wild-type T antigen.
The small decrease in the pRLSV40/pRLCMV measured in
the cell lines not replicating the SV40 origin containing plas-
mid may reﬂect slight diﬀerences in the quality of the plasm-
id preparations used for transfection. WI38 75.1, but not
AG11395, was capable of supporting the replication of the
SV40 origin containing plasmid when T-antigen was provid-
ed by co-transfection of pBRSV40. These results show that
SV40 origins of replications are not functional in AG11395
cells.
A short pulse (30min) of EdU (5-ethynyl-2 -deoxyuri-
dine) in S phase cell does not show a signiﬁcant diﬀerence in
theincorporationofEdUpatterninAG11395andWI3875.14 Journal of Oncology
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Figure 1: AG11395 does not support the replication of plasmids containing an SV40 origin of replication. (a) Three SV40-transformed cell
lines were transfected with pRLSV40, which contains an SV40 origin of replication and pRLCMV, which does not contain an SV40 origin,
in a 1:1 molar ratio along with pEGFP (as carrier DNA), or pBRSV40 (to supply wild-type T-antigen). Replication was measured by the
ratio of pRLSV40 to pRLCMV as determined by qPCR, normalized to the ratio in the input DNA. AG11395 does not support replication of
pRLSV40, even if wild-type T-antigen is provided by cotransfection. WI38 75.1 does support replication of pRLSV40, but only if wild-type
T-antigenisprovidedbycotransfection.COScellssupporteﬃcientreplicationofpRLSV40,withorwithoutadditionalT-antigenexpression.
(b)Ashortpulse(30min)ofEdU(5-ethynyl-2 -deoxyuridine)inAG11395andWI3875.1,Sphasecelldoesnotshowasigniﬁcantdiﬀerence
in the incorporation of EdU pattern in cells. Telomere pna FISH is (Cy3) red, EdU is (FITC) green, and DAPI-stained nuclei are blue.
cells (Figure 1(b)), again conﬁrming that SV40 origins in the
telomeres of AG011395 cells are not functional.
3.2. Exogenously Expressed WRN Colocalizes with Telomeres
in AG11395. In S. cerevisiae, ALT type I survivors with a tan-
dem array telomere structure initially arise, but grow poorly.
With continued passage, these are replaced by type II survi-
vors that have long, heterogeneous, TG1−3 repeats [16]. Sur-
vivors in S. cerevisiae tlc1sgs1 cultures maintain a clear type
I telomere structure and type II survivors do not arise, sug-
gesting that Sgs1 is important for the development of type II
survivors. WRN facilitates telomere recombination and can
complement sgs1 deﬁciency in type II ALT cells of S. cere-
visiae [30]. WRN also colocalizes with telomeres in human
ALT type II cells [13]. Given these observations, we investi-
gated the possible role of WRN in transition from a “type 1”
like ALT telomere structure into a “type II” like ALT telome-
re structure in human cells. We cloned the full-length WRN
coding sequence in retroviral vector pLXIN. AG11395 cells
were infected with empty and WRN expressing pLXIN.
Three WRN expressing clones (WRN1, WRN2, and WRN3)
andthreeempty-vectorclones(EV1,EV2,EV3)wereselected
for analysis. WRN expression was conﬁrmed by western
blot (Figure 2(a)) and indirect immunoﬂuorescence (IF)
(Figure 2(b)). We then determined the localization of WRN
in AG11395. Indirect Immunostaining of WRN and TRF1
revealedcolocalizationofWRNwithTRF1(datanotshown).
We further conﬁrmed WRN colocalization with telomere
DNA by detecting the telomere with peptide nucleic acid
ﬂuorescent in situ hybridization (PNA FISH) combined with
WRN IF (Figure 2(c)).
3.3. Sister Telomeres Loss (STL) Is Decreased in WRN Expres-
sing AG11395. The localization of WRN at telomeres sug-
gested that WRN might function in telomere metabolism
in AG11395. Increase in STL has been reported in WRN-
deﬁcient ﬁbroblasts and by the inhibition of WRN in HeLa
cells [31]. To determine if WRN is functioning at telomeres
when expressed in AG11395, we determined the frequency
of STL in three control retrovirus-infected and three WRN
expressing retrovirus-infected AG11395 subclones (Table 1).
The expression of WRN in AG11395 decreased the rate of
STLs from a mean of 10.4 per metaphase spread in the
three empty vector-infected AG11395 cells to 7.1, 6.9 and 4.4
per metaphase spread in the AG11395 WRN1, WRN2, and
WRN3 cells, respectively.
3.4.ExpressionofWRNIncreasesTelomereRepeatSequencesin
AG11395. In yeast, Sgs1-dependent transition of type I ALT
totypeIIALTtelomerestructuresisaccompaniedbyappear-
ance of long tracts of telomere repeats [17]. The presence
of WRN at telomeres suggested that reexpression of WRN
might similarly modulate the lengths of the telomere repeatJournal of Oncology 5
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Figure 2: WRN expression in AG11395 cells. (a) Western blot of WRN expression in AG11395 clones. 10ug of total protein was prepared
from the empty vector-infected and WRN expressing cell lines and blotted with the antibodies indicated. (b) WRN transgene expression in
AG11395 was analyzed by indirect immunoﬂuorescence (IF). WRN is present at increased concentration in the nucleoli of AG11395 cells
expressing the WRN transgene. (c) Exogenous WRN expressed in AG11395 colocalizes with telomeres. PNA FISH and IF were performed
withantibodiestoWRNandTRF1;nucleiwerevisualizedwithDAPI.(d)EﬀectofWRNexpressionontelomeresinAG11395cells.Telomere
length increases after WRN expression in AG11395 cells. Quantitation of telomere length was performed by PNA FISH in the three AG11395
empty-vector and three WRN expressing clones.
tracts in AG11395. We quantiﬁed telomere repeats by quan-
titative PNA FISH in control and WRN-expressing clones
(Figure 2(d)). We found that all three WRN expressing clo-
nes show increased telomere repeat signals at telomeres at
populationdoubling(PD)24(Table 2).TheWRNexpressing
clones AG11395 WRN1, WRN2, and WRN3 had mean telo-
mere sequence lengths of 807, 771 and 919 AFUs, as comp-
ared to the mean telomere sequence lengths in empty vector-
infected AG11395 cells EV1, EV2, and EV3 that measured
577, 547, and 449 AFUs, respectively.
3.5. SV40 Sequences Are Lost with Increasing Population Dou-
bling (PD) after WRN Expression in AG11395. In AG11395,
the repetitive structure at telomeres contains both telomere6 Journal of Oncology
Table 1: WRN and telomerase expression decreases sister telomere
loss (STL) in AG11395. Fifteen metaphases per cell line were
analyzed. P values indicated are from the Wilcoxon two-sided ranks
test, comparing the WRN and telomerase-expressing clones to the
pooled empty vector-infected controls.
Cell line STL/cell Signiﬁcance
AG11395 EV1 11.4
AG11395 EV2 9.2
AG11395 EV3 10.6
AG11395 WRN1 7.1 P<0.0005
AG11395 WRN2 6.9 P<0.01
AG11395 WRN3 4.4 P<0.0001
AG11395 hTERT 2.8 P<0.00001
Table 2: Eﬀects of WRN and telomerase expression in AGO11395
cells.
Empty vector WRN
expressing
Telomerase
expressing
AGO11395 AGO11395 AGO11395
STL/cell 9.2–11.4 4.4–7.1 2.8
SV40 origin
sequence loss — 20–25% 40–50%
Telomere length
in AFUs 449−577 771–919 872
APBs not present present not present
T-SCE 10.4% 11.9% 9.4%
and SV40 sequences [21]. In yeast, the transition from type I
ALT to type II ALT telomere structures involves loss of a tan-
dem array telomere structure and appearance of long tracts
of telomere repeats [17]. After observing an increase in telo-
mere sequence with expression of WRN protein in AG11395,
we determined whether SV40 sequences were decreasing. We
quantiﬁed the SV40 sequence by quantitative polymerase
chain reaction (qPCR) at PD 24, 54, and 70 (Figure 3). All
three WRN expressing clones showed a trend of decreasing
SV40 sequence with increasing PDs when compared with
the empty vector-infected clone at the same PD (Table 2).
As analyzed by FISH, SV40 sequences detectable in AG11395
colocalize with telomere sequences [20]. The overall loss of
SV40 sequences as measured by qPCR therefore indicates a
loss of SV40 sequences from telomeres.
3.6. ALT Associated PML Bodies (APBs) Are Present in WRN
Expressing AG11395 Cells. APBs are characterized by the co-
localization of the PML protein with telomere repeat binding
factors in ALT cells and have been used as morphologic
marker for the presence of ALT telomere maintenance [19].
The frequency of cells containing APBs is increased when
cultures are enriched for cells in the G2/M phase of the cell
cycle [32]. AG11395 cells do not contain APBs [20]. Instead,
they have nuclear aggregates containing SV40 large T anti-
gen and many of the same components as APBs. After WRN
expression in AG11395, we observed few spots of TRF1 and
PML colocalization in rare cells (data not shown). Follow-
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Figure 3: SV40 sequences decrease after WRN expression in
AG11395 cells. (a) The SV40 DNA content in the WRN expressing
AG11395 clones was determined by qPCR at the indicated popu-
lation doublings and normalized to the SV40 DNA content of the
emptyvectorinfectedcloneatthatpopulationdoubling.One-tailed
probability values of t-tests are indicated.
ing 1.5ug/mL nocodazole arrest to enrich the G2/M phase
cells we looked for APBs by combined IF/PNA FISH. After
analyzing 300 cells, we found that 3% of cells show telomere
and PML co-localization (Figure 4)a n d( Table 2).
3.7. Expression of hTERT Restores Telomerase Activity in
AG11395. AG11395 cells lacked detectable telomerase activ-
ityasmeasuredbythetelomererepeatampliﬁcationprotocol
(TRAP) assay (Figure 5(a)) and lack expression of human
telomerase reverse transcriptase (hTERT) mRNA by quanti-
tative reverse-transcriptase PCR (data not shown). Telom-
erase activity can be reconstituted in some type II ALT
cells by expression of hTERT [33]. To investigate if the ALT
type I like cells can reconstitute human telomerase reverse
transcriptase (hTERT) activity and alter telomere maintena-
nce we produced AG11395 expressing pBABE-puro-hTERT
[34]. Telomerase activity was assayed by TRAP [35] at PD10.
AG11395cellsexpresstelomeraseandbecomeTRAPpositive
(Figure 5(a)).
3.8.ExpressionofTelomeraseinAG11395CellsLengthensTelo-
meres, Decreases STLs, and Induces Loss of SV40 Sequences.
Expression of exogenous hTERT in ALT type II cells results
in lengthening ofthe shortest telomeres [33].WRN-deﬁcient
ﬁbroblasts have higher frequency of short telomeres and
STLs [31]. Telomerase preferentially acts on short telomeres
in WS ﬁbroblasts and thus reduces number of STLs [31].
Expression of telomerase in AG11395 cells resulted in
lengthening of short telomeres (Figure 5(b)). As expected,Journal of Oncology 7
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Figure 5: Expression of hTERT in AG11395 modulates telomere length. (a) TRAP assay on hTERT-expressing cell lines. Exogenous
expression of hTERT makes AG11395 cells TRAP positive. (b) Q-FISH of telomere repeat content in empty vector and mixed telomerase
expressing AG11395 cells. Expression of telomerase increased the median telomere repeat signal in the population and caused loss of the
telomeres with minimal detectable telomere repeat signal. (c) Q-PCR for SV40 sequences in the empty vector and hTERT expressing
AG11395 sublines. SV40 sequences rapidly decreased by more than 60% after hTERT expression in AG11395. With continued passage,
further loss of SV40 sequences was not observed.
the extension of short telomeres decreased the frequency of
STLs (Table 1).
We also quantiﬁed SV40 sequences in hTERT expressing
AG11395 cells by qPCR. Unlike WRN expression that caused
a slow, gradual reduction in SV40 sequence (Table 2)w i t h
increasing PDs, we found a greater initial decrease in SV40
sequence at PD10 with no signiﬁcant additional change over
80 PDs (Figure 5(c)).
3.9. Expression of WRN or Telomerase Did Not Change the
Rate of Telomere Sister Chromatid Exchange (T-SCE) in
AG11395. To understand the eﬀect of WRN expression on8 Journal of Oncology
telomere sister chromatid exchange we employed CO-FISH.
We did not observe a signiﬁcant change in the T-SCE in
WRN expressing cells when compared to empty vector-tran-
sfected AG11395 cells (Table 2). The rate of T-SCE in empty
vector-transfected, WRN-expressing and telomerase-expres-
sing AG11395 cells is 10.4%, 11.9%, and 9.4%, respectively.
4. Discussion
WS patients exhibit an increased incidence of mesenchymal
cancers compared with the general population, but little is
knownaboutthegeneticpathwaysperturbedinthesetumors
because few WS tumor-derived cell lines exist [10]. The
increased incidence of mesenchymal cancers in WS patients
is intriguing because many human sarcomas maintain telo-
meres by the ALT pathway [10]. When immortalized G5
mouse Terc
−/−Wrn
−/− clones are injected subcutaneously
intoseverecombinedimmunodeﬁciencymice,aberranttelo-
mere recombination coupled with the strong selective pres-
suretomaintaintelomerelengthintheabsenceoftelomerase
results in the activation of ALT tumors [12]. These ALT
tumorsappeared to be type II, butthe possibility of ALT type
I tumor formation by WRN-deﬁcient cells cannot be ruled
out.
It has been suggested that in S. cerevisiae ALT type I is
generated by the selection of cells in which successive recom-
bination events have taken place in subtelomeric regions
[36].WRNdeﬁciencycanfacilitatethesub-telomericrecom-
bination in human cells due to the extensive telomere seq-
uence loss during telomere replication [31] and homologous
recombination [37] and possibly by increased aberrant reco-
mbination between nonidentical (homeologous) DNA seq-
uences [30, 37] .S u r v i v o r so fs u c he v e n t sm a yg e n e r a t eA L T
that maintains telomeres through a mechanism analogous to
the type I survival pathway observed in sgs1,t e l o m e r a s e - n u l l
yeast. The Werner mutant, SV40-immortalized ALT cell line
AG11395 maintains telomeres in a mechanism similar to the
type I survival pathway of yeast [20, 21]. This cell line oﬀers
a unique system to investigate the role of WRN deﬁciency
and tandem array telomeres in human ALT telomere main-
tenance.
Cohen and Sinclair tested the eﬀect of reintroduction of
Sgs1 into type I yeast survivors. This resulted in telomeres
with telomere sequence tracts extended by about 300bp and
with decreased numbers of Y  elements, but it did not fully
convert the telomeres to a type II structure [17]. Our results
with reintroduction of WRN in AG11395 cells, with in-
creased numbers of telomere sequence repeats and decreased
SV40 sequences present at chromosome ends, are consistent
with experiments of reintroduction of Sgs1 in yeast Typ1
ALT [17]. These data support the hypothesis that Sgs1
and WRN promote telomere-telomere recombination that
results in extension of telomere sequence and reduction of
non-telomere sequence, possibly, by decrease in aberrant
recombination between nonidentical (homeologous), DNA
sequences and telomere sequence loss. The proposed role of
WRN in transforming type I ALT like telomeres to type-II-
like telomeres are summarized in Figure 6.
- Increased telomere recombination
- Recombination in nonidentical sequence
- Telomere sequence loss
- Increased T-SCE
- Recombination in subtelomericregion
- Selection of cell
- ALT activation
WRN expression
- Increase in telomere-telomere recombination
- Decrease in recombination of nonidentical sequence
- Less telomere sequence loss
- Gain in telomere sequence
- Loss of nontelomeric sequence
ALT type II like
- Appearance of ALT-associated PMLbodies
ALT type I like
cell
cell
-deﬁcient cell
WRN- and telomerase
Figure 6 :P r o p o s e dr o l eo fW R Ni nt r a n s f o r m a t i o no fA L Tt y p e
I like telomere to ALT type II like telomere. In the WRN- and
telomerase-deﬁcient cell, ALT is activated. Selection of a cell with
recombination in subtelomeric region gives rise to ALT type I like
telomere. WRN transduction transforms the ALT I like telomere to
A L Tt y p eI Il i k et e l o m e r e .
Autonomously replicating sequences (ARSs)i nSaccha-
romyces cerevisiae have been characterized as both origins
of DNA replication and as chromatin repressors/silencers.
Some (ARSs) that functions in a plasmid are silent as replica-
tion origins in their natural chromosomal context. The ori-
gin and the silencer activities of ARS are modulated by posi-
tion and chromatin environment. The silencing side of
ARSs is surfaced in the subtelomere regions, where they en-
hance and extend the repression signals emitted by the telo-
mere.Theeﬀectofsequenceelementsorchromatinstructure
on the function of SV40 origin of replication has also been
reported [38]. To avoid the sequence dependency, well-char-
acterized plasmids containing the SV40 origin have been
extensively used to study SV40 origin function in mam-
malian cells in the presence of large T antigen.
AG11395 maintains telomeres that have a tandem array
structure that contains SV40 sequences, including the SV40
origin of replication, and telomere repeats. To determine if
the SV40 origins are functional in AG11395 cells we used
a plasmid containing the SV40 origin of replication. We
found that unlike WI38 75.1 AG11395 does not support
replicationoftheSV40originofreplication,evenifwild-type
T-antigenisprovidedintrans.Themostextensivelyreported
reasons for failure of SV40 origin to support replicationJournal of Oncology 9
of plasmid are cellular inhibitory factors [39] or dominant
negative T antigen [40]. For example, WT1 encoded by the
Wilms’ tumor gene inhibits replication by binding to SV40
origin.Manycellularfactors,includingthecellularlateorigin
binding protein (LOB) protein (and possibly additional
origin-speciﬁc proteins), interact with T antigen to pre-
pare the SV40 origin for replication [41]. AG11395 cells may
be missing or contain mutated cellular factor(s) required for
normal functioning of the SV40 origin of replication.
Alternatively, T antigen functions as an oligomer [42].
Some mutant T antigens can be complemented in vivo by
providing a wild-type T antigen in trans, while others exhibit
a strong trans-dominant-negative phenotype [40]. Althou-
gh we do not have any direct evidence, but it is possible that
the T antigen expressed in AG11395 cells has a dominant ne-
gative phenotype for function at the SV40 origin of replica-
tion. This would most simply explain the failure to stimulate
replication at the SV40 origin in AG11395 when wild-type T
antigen was expressed.
The role of nonfunctional Y  elements to yeast type I sur-
vivors and the role of the SV40 origin of replication in
AG11395 telomeres remain unclear. They extend the net len-
gth of telomere with interspersed nontelomeric sequences
and may serve as chromatin repressors like the ARS in Y  ele-
ment of type I ALT telomere in yeast.
A small number of AG11395 cells express APBs after
WRN expression. Endogenous WRN colocalizes with PML
proteininALTcells[13].However,thereisnosimplecorrela-
tion between ALT activity level and the number of APBs
or APB-positive cells. The proportion of APB-positive cells
can be greatly increased by methionine starvation, by DNA-
damaging agents, or by restoring p53 function in ALT cells
[43, 44]. In each of these cases, the treatments that induced
APBs also caused growth arrest. An ectopically expressed
GFP-WRN partially colocalized in large nucleoplasmic foci
with the endogenous PML protein in UV-irradiated U-2OS
cells [45]. PML shell formation starts from the site of PML-
WRN contact and proceeds until the PML layer is formed on
entire surface of a WRN body [46].
AtpresentitisnotclearhowWRNfacilitatesAPBforma-
tion. One possibility is that WRN is modulating an arrest
phenotype. For example, Werner syndrome cells escape hy-
drogen-peroxide-induced cell proliferation arrest [47]. We
anticipate that, given the expression of T antigen, AG11395
cellsdonotarrestinG1phaseofcellcycle.However,itispos-
sible that restoring WRN facilitates the arrest of few cells ac-
companied by the induction of APBs in G2/M phase follow-
ing spontaneous oxidative damage.
The expression of telomerase in AG11395 resulted in a
rapid expansion of telomere sequences and in a decrease
in the frequency of STLs. Although the expression levels of
WRNproteinintheclonesthatwereselectedforanalysisvar-
ied signiﬁcantly, we did not observe any signiﬁcant correla-
tion in STL or telomere sequence gain with the level of WRN
expression. We observed rapid loss of SV40 sequences by PD
10 that persisted, but did not increase, over 80 PDs. As ALT
is a recombination-based mechanism, the rapid loss of SV40
sequences is consistent with increased deletions occurring
during homologous recombination in the absence of WRN
[37]. That no further loss of SV40 sequences was observed
after 10 PDs in the presence of increased telomere repeats is
consistent with the presence of telomere repeat tracts pro-
tecting the residual SV40 repeats and is in accord with the
more recent observation that telomerase acts at the majority
oftelomeresinthecellateachcelldivision[48].Iftelomerase
only acted on the shortest telomeres in the cell, a continued
declineinthepresenceofSV40sequencesattelomereswould
be expected as the longer SV40 containing telomeres over
time reach the “critical” length and are subsequently ex-
tended by telomerase.
5. Conclusion
Our results indicate that the Werner protein plays a funda-
mental role in determining the telomere maintenance mech-
anisms in transformed cells. In the human WRN mutant
cell line AG11395, exogenous expression of Werner protein
facilitatesthetransitionofALTtypeIliketelomerestotypeII
like telomeres. The increased incidence of mesenchymal can-
cers observed in WS patients may relate to the nature of the
telomere maintenance program activated in these tumors.
Besides giving valuable diagnostic and prognostic infor-
mation, telomere maintenance mechanisms are a potential
therapeutic target for cancer treatment. The status of Werner
protein expression in tumor cells may be helpful in designing
therapeutic strategies.
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